BioSpace News Archive

MorphoSys AG announced Thursday it plans to drop its pre-clinical programs and cut 17% of its workforce in an effort to extend its cash runway.

Eli Lilly is expanding its pain management pipeline with a new asset from Belgium-based Confo Therapeutics targeting the angiotensin II type 2 receptor.

Results from the largest-ever trial of a four-day workweek showed overwhelming success, but is that success possible for biopharma companies?

Thymmune is backed by an A-list team of investors including Pillar VC, former Alnylam CEO John Maraganore and famed geneticist George Church.

Novo Nordisk announced Thursday it plans to expand its research and development operations in the greater Boston area and add over 200 new jobs this year.

Xilio Therapeutics, Inc. announced pipeline progress and business updates and reported financial results for the fourth quarter and full year ended December 31, 2022.

Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update.

INmune Bio, Inc. announces its financial results for the year ended December 31, 2022 and provides a business update.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that the Company will release its fourth quarter 2022 financial results on Thursday, March 9, 2023, after the close of U.S. markets.

Arcus Biosciences, a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will participate in a fireside chat at the upcoming Barclays Global Healthcare Conference in Miami Beach, Florida.